Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity - Test2 - elhamkhani - TriplyDB

Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity

Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT3A, TPMT2): mechanisms for the genetic polymorphism of TPMT activity

http://www.wikidata.org/entity/Q24682894

about

Very important pharmacogene summary: thiopurine S-methyltransferase Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity Drug methylation in cancer therapy: lessons from the TPMT polymorphism Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid Molecular cloning and functional characterization of the cDNA encoding the murine thiopurine S-methyltransferase (TPMT)Assessment of Thiopurine-based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia Four human thiopurine s-methyltransferase alleles severely affect protein structure and dynamics Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation.Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme.Polymorphisms and disease: hotspots of inactivation in methyltransferases Pharmacogenetics of cancer therapy: getting personal Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.Recent advances in the pharmacogenomics of thiopurine methyltransferase.The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.Pharmacogenetics in diverse ethnic populations--implications for drug discovery and development.Thiopurine S-methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian population.The emergence of resistance to targeted cancer therapeutics.A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.Pharmacogenomics: marshalling the human genome to individualise drug therapy Cancer pharmacogenomics: SNPs, chips, and the individual patient.Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines.Pharmacogenomics: bench to bedside.Frequency of thiopurine S-methyltransferase mutant alleles in indigenous and admixed Guatemalan patients with acute lymphoblastic leukemia.Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine.Pharmacogenetics and diseases of the colon.The role of pharmacogenetics in cancer therapeutics.Genetic variants and the risk of Crohn's disease: what does it mean for future disease management?Review article: thiopurines in inflammatory bowel disease.Clinical application of pharmacogenetics in gastrointestinal diseases.The pharmacogenetics research network: from SNP discovery to clinical drug response.Nomenclature for alleles of the thiopurine methyltransferase gene.Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.PhRMA white paper on ADME pharmacogenomics.Gene polymorphisms and pharmacogenetics in rheumatoid arthritis Part 1: background, methodology, and clinical adoption of pharmacogenetics.Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

P2860

Q24601748-9C201C58-E7CA-4971-AB73-BE23E2457490 Q28068930-4DE66C89-A3F5-41E9-9B19-4AD780ABA983 Q28115755-3EF02366-3555-4B80-AC64-0629969D4670 Q28212325-2F7C076B-A8D9-4ADC-8BBC-16190966AC32 Q28367534-2BC5D760-9AE6-48A5-AF9C-B03212757BAE Q28538238-0677EE50-306C-47DF-85E5-EF7BD8E102CE Q28587435-1EF04B27-0B68-4F5D-9EE2-4B160B15B134 Q28612763-C564A9AE-0B74-4CBC-BA94-797CED7D8E8F Q30369449-EE5B0520-3D1F-43AB-912C-8718AAE8D648 Q33372321-8BD4346D-E34E-4C9C-BA96-E53C18A764CF Q33625656-6AC20407-B13D-44FD-909C-76D12F26A5D3 Q34084734-6FD4DD1F-B1D8-4965-920F-13B19E21C525 Q34386321-4953A3EB-DEBF-41E0-8A16-1263D5FEF7F7 Q34459885-B0ECAA47-9186-4FF3-B689-57A0EB0E9F5F Q34574036-659B853F-36AD-4107-ABBC-BB1670DC72B8 Q34609157-3F105B83-A24D-4734-88AE-1A6F0F2A28C1 Q34775319-620D57AB-3E07-4172-BBB4-2219FFE890B0 Q34793050-D7F6095E-8659-4AD4-8006-33928BD9AE0E Q34837015-B9E98026-5225-4892-9F4C-BE65C7B17BD8 Q34989475-CF700B9A-0456-428E-AB23-BAFAD7D19016 Q34996171-6AAA3BC1-EF6F-4C17-879D-F64BB89429EA Q35090217-1DB25C14-AADA-473F-94B0-EA3A70014D9C Q35553873-289F2AFD-E83A-40D5-AAD7-08DE53851CF1 Q35646066-11B7FA51-1094-42EF-BFE9-C7C224C818C4 Q35876017-D9DA95B7-BBD1-40AA-A2DD-81833C1ADD3C Q35984724-2D2D0EBA-A831-4228-9061-D2BBA0FE25F3 Q35988128-2B86CB4C-C291-40BC-A9E8-E9B44B13BE15 Q36053671-8D8860A1-DA6C-47D3-BAC1-8018B9C6C0AE Q36404764-B279E52F-8C7A-4482-8EFE-B657A8A71A37 Q36536674-C8416439-66CA-4160-8240-C1336D6F03A9 Q36548717-D6E245B4-92DA-44FA-97BB-83E1F053330B Q36570796-1026A618-8A3D-4471-B1CC-128D125DC59A Q36613862-1AF11955-B6F6-44BE-9152-498A7F81D157 Q36752662-91741EEB-4CDA-4472-8A63-B7B4CCB7D711 Q37056505-6F65999F-8848-4CF8-B676-CAAB1533EFAD Q37163352-00F158A4-4517-474E-8B91-FE56FB6DAC80 Q37182212-EA034AE5-DFFB-4261-81E1-F329D493F462 Q37214931-F438DFC2-6149-4391-AB37-AB2BDA1F59A3 Q37883726-9A3E33CC-1CBB-4E47-BCE6-DD4E4C963E2F Q37887337-C9FD253C-485E-4DF3-8F5C-5925CE0E05D7

P2860

Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT3A, TPMT2): mechanisms for the genetic polymorphism of TPMT activity

http://www.wikidata.org/entity/Q24682894

description

1997 nî lūn-bûn

@nan

1997 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Enhanced proteolysis of thiopu ...... polymorphism of TPMT activity

@ast

Enhanced proteolysis of thiopu ...... polymorphism of TPMT activity

@en

Enhanced proteolysis of thiopu ...... polymorphism of TPMT activity

@nl

type

label

Enhanced proteolysis of thiopu ...... polymorphism of TPMT activity

@ast

Enhanced proteolysis of thiopu ...... polymorphism of TPMT activity

@en

Enhanced proteolysis of thiopu ...... polymorphism of TPMT activity

@nl

prefLabel

Enhanced proteolysis of thiopu ...... polymorphism of TPMT activity

@ast

Enhanced proteolysis of thiopu ...... polymorphism of TPMT activity

@en

Enhanced proteolysis of thiopu ...... polymorphism of TPMT activity

@nl

P1433

Q24682894-C4633039-94E4-4887-95DC-CD6E893495BD

P1476

Q24682894-A7B58A11-5174-42E6-8F27-22125A92C0C0

P2093

Q24682894-2761B454-D1D2-4769-ADA2-7FB380465BCA

Q24682894-81106370-29B0-41F7-8F0D-1A9A65F81B90

Q24682894-9757AE0E-3EDB-4806-9979-05226E7AA609

Q24682894-9C7998E1-98DD-4AF7-B28B-EE70E711A13D

Q24682894-C5A4F65A-7301-4E96-BA0D-D6E0C33DE780

P2860

Q24682894-05997058-8E77-4ED6-B889-C14F35FDF7CF

Q24682894-0C0FA888-072A-4765-A574-C91339860075

Q24682894-25AA265A-6DCA-418C-AE37-A0F764A5BA24

Q24682894-2CD7ECCD-C773-4D84-B545-E0B00944013A

Q24682894-3655F6DA-0AAF-4130-85F0-9D9260C75B14

Q24682894-395CA015-0792-4663-BD68-366EAA7C6F84

Q24682894-4F570582-55B9-48D7-B72E-0407076BA973

Q24682894-51B39C67-64C4-4494-8557-C41C0E644CDF

Q24682894-51B72760-388D-46F3-ABD2-0D74FFFD0869

Q24682894-5CDE28D3-18B9-4644-A7C2-850C8EF88224

P304

Q24682894-A8296A0C-89EB-433E-BA17-C2CDFE111F2E

P31

Q24682894-12B68E4E-139C-4392-9539-7FE64266AAB2

P3181

Q24682894-F3A8310C-27BA-45F7-8602-EC4A1D1F105C

P356

Q24682894-99A96266-FE67-4E74-825D-B9B84407EA48

P407

Q24682894-234B2C48-4D90-4084-9F49-2EC7B187D09C

P433

Q24682894-F7F37C64-28CC-43EA-8A18-08C8B601701A

P478

Q24682894-F07BDF72-13DE-4ABE-A02D-A4A11A1EDCFB

P577

Q24682894-EE521324-649D-4F2F-9C2C-D10F9D5872C7

P5875

Q24682894-7563CE1F-3DA3-46E3-B247-36187150EAF5

P698

Q24682894-AD9E2BC8-96CE-49EE-B729-BFE795EC1046

P921

Q24682894-C7C51E6A-604C-4C67-8A13-D49BC0312777

P932

Q24682894-A0070C4D-79AD-4A64-BFC1-9500A0F21593

P3181

P356

PNAS.94.12.6444

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Enhanced proteolysis of thiopu ...... polymorphism of TPMT activity

@en

P2093

E G Schuetz

http://www.w3.org/2001/XMLSchema#string

E Y Krynetski

http://www.w3.org/2001/XMLSchema#string

H L Tai

http://www.w3.org/2001/XMLSchema#string

W E Evans

http://www.w3.org/2001/XMLSchema#string

Y Yanishevski

http://www.w3.org/2001/XMLSchema#string

P2860

Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA

A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase

Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity

Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians

Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism

In vivo half-life of a protein is a function of its amino-terminal residue

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

Mutation in the CYP21B gene (Ile-172----Asn) causes steroid 21-hydroxylase deficiency.

Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.

The purine path to chemotherapy.

P304

6444-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3616141

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.94.12.6444

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

1997-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14042026

http://www.w3.org/2001/XMLSchema#string

P698

9177237

http://www.w3.org/2001/XMLSchema#string

P921

P932

21069

http://www.w3.org/2001/XMLSchema#string